Israeli firms BioLineRx, Compugen team to pursue inflammation, cancer drugs
This article was originally published in Scrip
Executive Summary
Israeli firms BioLineRx and Compugen have teamed up to develop and commercialize treatments for acute and chronic inflammatory disease, cardiovascular disease, retinopathy and cancer, along with other conditions.